巴曲酶治疗突发性聋的临床分析

目的评估巴曲酶治疗突发性聋的效果。方法180例病因不明的突发性聋患者分为3组,分别为丹参 激素组(对照组),丹参 激素 巴曲酶组,丹参 巴曲酶组(激素治疗禁忌)开展平行对照研究。在药物治疗的同时进行高压氧治疗。结果除去不良反应、治疗依从性差等病例,将剩下的164例进行最终统计,分别为巴曲酶 激素组 丹参58例,巴曲酶 丹参组53例,丹参 激素组53例。结果显示,初始听力表现为下坡型、平坦型、极重度型和全聋型的患者,治疗方式对前三种听力曲线患者预后的影响差异无显著性,而全聋组的病例巴曲酶治疗的两组与激素组之间疗效差异有显著性(巴曲酶 丹参 激素组、巴曲酶 丹参组显效率分别为75%、62.5%,丹参 激素组为28.6%,P<0.005);而巴曲酶治疗的两组之间疗效无显著性差异(P>0.05)。结论全聋型的突发性聋治疗中早期进行巴曲酶降纤治疗,可能会获得较为满意的疗效。

The clinical efficacy of batroxobin in sudden sensorineural hearing loss

Objective To evaluate the efficacy of batroxobin in the management of patients with sudden sensorineural hearing loss. Methods One hundred and eighty patients with sudden hearing loss were included in the present study and were divided into three groups. Group I patients were treated with Salvia miltiorrhiza and dexamethasone (control group). Group II patients were treated with Salvia miltiorrhiza, dexamethasone and batroxobin. Group III patients were treated with Salvia miltiorrhiza and batroxobin. All patients also underwent an associated hypobaric oxygen therapy. Results Sixteen patients due to side effect or uncompliance were withdrawn from the trial. Consequently, the study participants consisted of 53 patients in Group I, 58 patients in group II, and 53 patients in group III, respectively. Their initial audiograms were slop, flat, profound or total deafness type, respectively. The hearing improvement was not significantly different among patients with slop, flat or profound hearing loss audiogram, while patients with total deafness treated with batroxobin (group II and III) showed statistically significant (P < 0.005) hearing improvement more than patients treated with dexamethasone(group I). Hearing improvement in group II and group III was not different between patients with total deafness. Conclusion Greater degree of hearing improvement was achieved in patients with total deafness treated with Batroxobin.